Deuterated analogs of D-serine and uses thereof
This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
1. A method of treating schizophrenia, the method comprising administering to a subject in need thereof an effective amount of Compound 100:
wherein Compound 100 is at least about 90% stereomerically pure, and
wherein in compound 100 the position designated specifically as deuterium has at least 90% incorporation of deuterium;
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the method further comprises administering an antipsychotic therapeutic agent to the subject.
3. The method of claim 1 , wherein in Compound 100, the position designated specifically as deuterium has at least 95% incorporation of deuterium.
4. The method of claim 1 , wherein in Compound 100, the position designated specifically as deuterium has at least 97% incorporation of deuterium.
5. The method of claim 1 , wherein in Compound 100, any atom not designated as deuterium is present at its natural isotopic abundance.
6. The method of claim 1 , wherein Compound 100 is administered in a pharmaceutical composition that is suitable for oral administration.
7. The method of claim 1 , wherein the method comprises administering an amount of Compound 100 in the range of 1 g to 4 g.
8. The method of claim 1 , wherein less than 2% of the enantiomer of Compound 100 is present.
9. The method of claim 1 , wherein the method comprises administering an amount of Compound 100 in the range of 1 to 4 g per day.